--- title: Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients. nct_id: NCT02029222 overall_status: COMPLETED sponsor: Maastricht Radiation Oncology study_type: OBSERVATIONAL primary_condition: NSCLC countries: Netherlands canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02029222.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02029222" ct_last_update_post_date: 2019-09-04 last_seen_at: "2026-05-12T07:08:55.185Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients. **Official Title:** In Silico Clinical Trial on Re-irradiation Lung Cancer, Comparing Photon, Proton and 12C-ion Therapy: A Multicentric ROCOCO Planning Study Based on a Reference Dataset of Patients. **NCT ID:** [NCT02029222](https://clinicaltrials.gov/study/NCT02029222) ## Key Facts - **Status:** COMPLETED - **Study Type:** OBSERVATIONAL - **Target Enrollment:** 25 - **Lead Sponsor:** Maastricht Radiation Oncology - **Collaborators:** University of Pennsylvania, University of Wisconsin, Madison - **Conditions:** NSCLC - **Start Date:** 2013-12 - **Completion Date:** 2019-09 - **CT.gov Last Update:** 2019-09-04 ## Brief Summary Patients with lung cancer may develop a second primary tumor or recurrent disease after previous radiotherapy. Surgical salvage therapy is the mainstay of therapeutic options. However, in case of irresectable disease, re-irradiation should be considered. Also in the postoperative setting, re-irradiation is considered after surgical salvage in case of features in the pathology specimen indicating a high risk for subsequent recurrence. However after re-irradiation, there is a high risk of 43% grade 3 (late) toxicity at 5 years (including possible fatal complications) and a relatively low chance of locoregional control of 50% at 5 years. One out of three patients survives re-irradiation without recurrence and severe complications. Improvements in both the risk of radiation-induced complications and the oncological outcome are thus warranted. Compared to conventional radiotherapy with photons (CRT), particle therapy (PT) has the potential to inflict maximum damage on tumors with minimum collateral damage to neighboring healthy tissue. Given that the cost of particle therapy (PT) is considerably higher than that of conventional radiotherapy (RT) with photons, it is necessary to establish whether these higher costs are worthwhile in light of the expected advantages. Thus, clear evidence of the situations in which PT outperforms conventional photon treatment is needed. Publications on this topic are rare. The only recent publication has analyzed the results of 37 NSCLC patients of whom 9 were re-irradiated with at least 50 Gy using helical tomotherapy \[Kruser in press\]. We propose an in silico trial to investigate to what extend proton and 12C-ion therapy decrease the amount of irradiated normal tissue in lung cancer patients treated with radiotherapy after an initial radiotherapy treatment. ## Detailed Description For this in silico planning study all treatment plans will be performed in centers that are already operating and have experience in treatment planning. Photon treatment plans will be carried out in Maastricht, proton treatment plans at the University of Pennsylvania and the C-ion treatment plans at the University of Wisconsin. A dataset with state-of-the-art image data is available. 25 patients will be included according to a-priori defined selection criteria. Each patient will function as his or her own control. For this reason, the number of patients per tumor group can be limited to 25 patients per tumor group (power = 80%, alpha = 5%). The datasets will be stored on a secure website hosted by MAASTRO. High quality CT-images will be used for radiotherapy treatment planning. If available, secondary image information such as FDG-PET and MRI will be used for GTV delineation. All relevant OARs will be delineated in both the primary and secondary studyset. GTV/CTV will be used accordingly to the actual treatment. New DVH's will be calculated for the added OAR. Dose restrictions for the re-irradiation plan will be defined for each individual patient based on the DVH dose in the primary photon treatment plan. Photons will be planned with direct Aperture Optimized Intensity Modulated Radiotherapy (IMRT). Protons will be planned using active beam delivery with Intensity Modulated proton therapy (IMPT)and carbon-ions with a pencil beam delivery treatment planning technique with gantry. Each participating center will use its own treatment planning system according to standard practice at that center. The GTV to PTV margin will be determined by the individual institutes according to the treatment technique and treatment modality. The same tumor dose, overall treatment time (OTT) and an equal number of fractions will be used for all treatment modalities. Photon, proton and C-ion treatments will be compared based on dosimetric parameters on normal tissues. In addition, the NTCP for a fixed tumor dose or the same expected TCP will be determined. Cobalt Gy equivalent doses will be used when reporting the proton and carbon-ion dose. In the case of protons, a constant RBE value of 1.1 will be used for both the tumor and the normal tissues. The RBE of carbon-ions will be calculated based on the models used by the participating centers. Dose in the following structures will be taken into account: * Lungs * Spinal court * Heart * Oesophagus ## Eligibility - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Re-irradiation patients for relapsed or second cancers in the left or the right lung * Received respitory gated CT (4DCT) and PET (4DPET) scans. * The primary treatment was radiotherapy with a curative intent * The organs at risk of the primary tumor treatment are the same organs at risk at the secondary treatment * 18 years or older ``` ## Arms - **25 NSCLC patients** — 25 NSCLC patients who received curative radiotherapy. Re-irradiation can either be indicated for primary or secondary cancers in the lung. All patients referred for primary radiotherapy or chemoradiation after curative radiation therapy more or equal to one year ago with overlapping CTV will be included. The organs at risk of the primary tumor are the same organs at risk at the secondary treatment. ## Primary Outcomes - **The amount of irradiated normal tissue: lung** _(time frame: Up to ten months (planning time))_ — \- lung: V30, V20, V13, V5, mean lung dose - **The amount of irradiated normal tissue: Spinal cord** _(time frame: Up to ten months)_ — Spinal cord: Dmax - **The amount of irradiated normal tissue: esophagus** _(time frame: Up to ten months)_ — Esophagus: Dmax, mean dose (MD), V55, V35 - **The amount of irradiated normal tissue: Heart** _(time frame: Up to ten months)_ — Heart: Total dose (TD), V65, V45, V40, V30, V20, V10, MD - **The amount of irradiated normal tissue: Integral dose** _(time frame: Up to ten months)_ — Integral dose ## Secondary Outcomes - **Risk of side effects in the irradiated normal tissue** _(time frame: Up to ten months)_ ## Locations (1) - Maastricht Radiation Oncology, Maastricht, Netherlands ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.maastricht radiation oncology|maastricht||netherlands` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02029222.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02029222* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*